Rosiglitazone in the Assistance of Metabolic Control during Olanzapine Administration in Schizophrenia: A Pilot Double-blind, Placebo-controlled, 12-week Trial

被引：35
作者：
Baptista, T. [1 ]
Rangel, N. [2 ]
El Fakih, Y. [3 ]
Uzcategui, E. [3 ]
Galeazzi, T. [4 ,5 ]
Beaulieu, S.
de Baptista, E. Araujo [6 ]
机构：
[1] Univ Los Andes, Dept Physiol, Sch Med, Merida 5101A, Venezuela
[2] Psychiat Inst Dr Raul Castillo, San Cristobal, Tachira State, Venezuela
[3] Univ Los Andes, Dept Psychiat, Sch Med, Merida, Venezuela
[4] Univ Los Andes, LABIMET, Sch Med, San Cristobal, Venezuela
[5] McGill Univ, Douglas Hosp, Res Ctr, Montreal, PQ, Canada
[6] Univ Los Andes, Sch Pharm, Dept Microbiol, Sch Med, Merida, Venezuela
来源：
PHARMACOPSYCHIATRY | 2009年 / 42卷 / 01期
关键词：
WEIGHT-GAIN; INSULIN-RESISTANCE; ATYPICAL ANTIPSYCHOTICS; METFORMIN; RISK; THIAZOLIDINEDIONES; RISPERIDONE; THERAPY; GLUCOSE;
D O I：
10.1055/s-0028-1085438
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Introduction: Excessive body weight gain (BWG), hyperglycemia and dyslipidemia are important side effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the insulin resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in olanzapine-treated schizophrenia patients. Methods: Thirty patients taking olanzapine (10-20mg daily for 8 months) were randomly allocated to rosiglitazone (n=15: 4 to 8 mg daily) or placebo (n=15) in a 12-week double-blind protocol. Anthropometric and biochemical variables were evaluated at baseline, weeks 6 and 12. Results: The rosiglitazone and placebo groups gained 3.2 +/- 4.5 and 2.2 +/- 2.3kg, respectively (p=0.65). Insulin and the HOMA-IR significantly decreased after rosiglitazone (p<0.05). Rosiglitazone did not improve the lipid profile, fibrinogen and Hb1c levels. Discussion: The positive impact of rosiglitazone was limited to improved glycemic control. It cannot be recommended for metabolic control during olanzapine treatment.
引用
收藏
页码：14 / 19
页数：6
相关论文
共 35 条
[1]   Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease - A placebo-controlled study of olanzapine and risperidone in dogs [J].
Ader, M ;
Kim, SP ;
Catalano, KJ ;
Ionut, V ;
Hucking, K ;
Richey, JM ;
Kabir, M ;
Bergman, RN .
DIABETES, 2005, 54 (03) :862-871
[2]   Metformin for prevention of weight gain and insulin resistance with olanzapine:: A double-blind placebo-controlled trial [J].
Baptista, T ;
Martínez, J ;
Lacruz, A ;
Rangel, N ;
Beaulieu, S ;
Serrano, A ;
Arapé, Y ;
Martinez, M ;
de Mendoza, S ;
Teneud, L ;
Hernández, L .
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2006, 51 (03) :192-196
[3]   Drug induced weight gain, an impediment to successful pharmacotherapy:: Focus on antipsychotics [J].
Baptista, T ;
Zárate, J ;
Joober, R ;
Colasante, C ;
Beaulieu, S ;
Páez, X ;
Hernández, L .
CURRENT DRUG TARGETS, 2004, 5 (03) :279-299
[4]   Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration:: A multicentric, double-blind, placebo-controlled trial [J].
Baptista, Trino ;
Rangel, Nairy ;
Fernandez, Virginia ;
Carrizo, Edgardo ;
El Fakih, Yarnily ;
Uzcategui, Euderruh ;
Galeazzi, Tatiana ;
Gutierrez, Maria A. ;
Servigna, Mercedes ;
Davila, Adriana ;
Uzcategui, Marycelvia ;
Serrano, Ana ;
Connell, Lisette ;
Beaulieu, Serge ;
de Baptista, Enma Araujo .
SCHIZOPHRENIA RESEARCH, 2007, 93 (1-3) :99-108
[5]   Weight loss in overweight patients maintained on atypical antipsychotic agents [J].
Centorrino, F. ;
Wurtman, J. J. ;
Duca, K. A. ;
Fellman, V. H. ;
Fogarty, K. V. ;
Berry, J. M. ;
Guay, D. M. ;
Romeling, M. ;
Kidwell, J. ;
Cincotta, S. L. ;
Baldessarini, R. J. .
INTERNATIONAL JOURNAL OF OBESITY, 2006, 30 (06) :1011-1016
[6]  
CHEN CH, 2007, PROG NEUROPSYCH 1117
[7]   Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder [J].
De Hert, Marc ;
Kalnicka, Dita ;
van Winkel, Ruud ;
Wampers, Martien ;
Hanssens, Linda ;
Van Eyck, Dominique ;
Scheen, Andre ;
Peuskens, Joseph .
JOURNAL OF CLINICAL PSYCHIATRY, 2006, 67 (12) :1889-1896
[8]   Interventions to reduce weight gain in schizophrenia [J].
Faulkner, G. ;
Cohn, T. ;
Remington, G. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (01)
[9]   Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance -: The Insulin Resistance Atherosclerosis Study (IRAS) [J].
Festa, A ;
D'Agostino, R ;
Mykkänen, L ;
Tracy, RP ;
Zaccaro, DJ ;
Hales, CN ;
Haffner, SM .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (03) :562-568
[10]   Long-term treatment with atypical antipsychotics and the risk of weight gain - A literature analysis [J].
Gentile, S .
DRUG SAFETY, 2006, 29 (04) :303-319
1234